Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 33

1.

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.

Jones RB, Tervaert JW, Hauser T, Luqmani R, Morgan MD, Peh CA, Savage CO, Segelmark M, Tesar V, van Paassen P, Walsh D, Walsh M, Westman K, Jayne DR; European Vasculitis Study Group.

N Engl J Med. 2010 Jul 15;363(3):211-20. doi: 10.1056/NEJMoa0909169.

2.

Pulse versus daily oral cyclophosphamide for induction of remission in antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial.

de Groot K, Harper L, Jayne DR, Flores Suarez LF, Gregorini G, Gross WL, Luqmani R, Pusey CD, Rasmussen N, Sinico RA, Tesar V, Vanhille P, Westman K, Savage CO; EUVAS (European Vasculitis Study Group).

Ann Intern Med. 2009 May 19;150(10):670-80.

PMID:
19451574
3.

Azathioprine or methotrexate maintenance for ANCA-associated vasculitis.

Pagnoux C, Mahr A, Hamidou MA, Boffa JJ, Ruivard M, Ducroix JP, Kyndt X, Lifermann F, Papo T, Lambert M, Le Noach J, Khellaf M, Merrien D, Puéchal X, Vinzio S, Cohen P, Mouthon L, Cordier JF, Guillevin L; French Vasculitis Study Group.

N Engl J Med. 2008 Dec 25;359(26):2790-803. doi: 10.1056/NEJMoa0802311.

4.

Predictors of treatment resistance and relapse in antineutrophil cytoplasmic antibody-associated small-vessel vasculitis: comparison of two independent cohorts.

Pagnoux C, Hogan SL, Chin H, Jennette JC, Falk RJ, Guillevin L, Nachman PH.

Arthritis Rheum. 2008 Sep;58(9):2908-18. doi: 10.1002/art.23800.

5.

Statistics in medicine--reporting of subgroup analyses in clinical trials.

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM.

N Engl J Med. 2007 Nov 22;357(21):2189-94. No abstract available.

6.

ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis.

Finkielman JD, Lee AS, Hummel AM, Viss MA, Jacob GL, Homburger HA, Peikert T, Hoffman GS, Merkel PA, Spiera R, St Clair EW, Davis JC Jr, McCune WJ, Tibbs AK, Ytterberg SR, Stone JH, Specks U; WGET Research Group.

Am J Med. 2007 Jul;120(7):643.e9-14.

PMID:
17602941
7.

Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial.

Stone JH, Holbrook JT, Marriott MA, Tibbs AK, Sejismundo LP, Min YI, Specks U, Merkel PA, Spiera R, Davis JC, St Clair EW, McCune WJ, Ytterberg SR, Allen NB, Hoffman GS; Wegener's Granulomatosis Etanercept Trial Research Group.

Arthritis Rheum. 2006 May;54(5):1608-18.

8.

Rituximab for refractory Wegener's granulomatosis: report of a prospective, open-label pilot trial.

Keogh KA, Ytterberg SR, Fervenza FC, Carlson KA, Schroeder DR, Specks U.

Am J Respir Crit Care Med. 2006 Jan 15;173(2):180-7. Epub 2005 Oct 13.

9.

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis.

De Groot K, Rasmussen N, Bacon PA, Tervaert JW, Feighery C, Gregorini G, Gross WL, Luqmani R, Jayne DR.

Arthritis Rheum. 2005 Aug;52(8):2461-9.

10.

Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).

Seo P, Min YI, Holbrook JT, Hoffman GS, Merkel PA, Spiera R, Davis JC, Ytterberg SR, St Clair EW, McCune WJ, Specks U, Allen NB, Luqmani RA, Stone JH; WGET Research Group.

Arthritis Rheum. 2005 Jul;52(7):2168-78.

11.

Evaluation of a new fluorescent-enzyme immuno-assay for diagnosis and follow-up of ANCA-associated vasculitis.

Damoiseaux JG, Slot MC, Vaessen M, Stegeman CA, Van Paassen P, Tervaert JW.

J Clin Immunol. 2005 May;25(3):202-8.

PMID:
15981084
12.

Randomized controlled trials in vasculitis associated with anti-neutrophil cytoplasmic antibodies.

Goek ON, Stone JH.

Curr Opin Rheumatol. 2005 May;17(3):257-64. Review.

PMID:
15838233
13.

Etanercept plus standard therapy for Wegener's granulomatosis.

Wegener's Granulomatosis Etanercept Trial (WGET) Research Group.

N Engl J Med. 2005 Jan 27;352(4):351-61.

14.
15.

Pathogenic roles of B cells in human autoimmunity; insights from the clinic.

Martin F, Chan AC.

Immunity. 2004 May;20(5):517-27. Review.

16.

Giant-cell granuloma of the respiratory tract (Wegener's granulomatosis).

WALTON EW.

Br Med J. 1958 Aug 2;2(5091):265-70. No abstract available.

17.

Limited versus severe Wegener's granulomatosis: baseline data on patients in the Wegener's granulomatosis etanercept trial.

Stone JH; Wegener's Granulomatosis Etanercept Trial Research Group.

Arthritis Rheum. 2003 Aug;48(8):2299-309.

18.

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies.

Jayne D, Rasmussen N, Andrassy K, Bacon P, Tervaert JW, Dadoniené J, Ekstrand A, Gaskin G, Gregorini G, de Groot K, Gross W, Hagen EC, Mirapeix E, Pettersson E, Siegert C, Sinico A, Tesar V, Westman K, Pusey C; European Vasculitis Study Group.

N Engl J Med. 2003 Jul 3;349(1):36-44.

19.

The mechanisms of action of rituximab in the elimination of tumor cells.

Johnson P, Glennie M.

Semin Oncol. 2003 Feb;30(1 Suppl 2):3-8. Review.

PMID:
12652458
20.

Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy.

Specks U, Fervenza FC, McDonald TJ, Hogan MC.

Arthritis Rheum. 2001 Dec;44(12):2836-40.

PMID:
11762944
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk